[3-[3-(Oxan-4-ylmethylsulfanyl)phenyl]-3-oxopropyl]carbamic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [3-[3-(Oxan-4-ylmethylsulfanyl)phenyl]-3-oxopropyl]carbamic acid
• 英文别名: [3-[3-(oxan-4-ylmethylsulfanyl)phenyl]-3-oxopropyl]carbamic acid
• 化学式: C₁₆H₂₁NO₄S
• 分子量: 323.4
• InChiKey: ASYIYZQIWRPGJQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS
  申请人：Acucela Inc.

  公开号：US20160229831A1

  公开（公告）日：2016-08-11

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明涉及治疗神经退行性疾病和疾病的组合物和方法，特别是眼科疾病和疾病。本文提供了替代的3-苯基丙胺衍生物化合物和包含该化合物的药物组合物。所述组合物对于治疗和预防眼科疾病和疾病，包括年龄相关性黄斑变性（AMD）和Stargardt病具有用处。
• US20140275043A1
  申请人：——

  公开号：US20140275043A1

  公开（公告）日：2014-09-18
• US9133154B2
  申请人：——

  公开号：US9133154B2

  公开（公告）日：2015-09-15
• [EN] SUBSTITUTED 3-PHENYLPROPYLAMINE DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISEASES AND DISORDERS<br/>[FR] DÉRIVÉS DE 3-PHÉNYLPROPYLAMINE SUBSTITUÉS POUR LE TRAITEMENT DES MALADIES ET DES TROUBLES OPHTALMIQUES
  申请人：ACUCELA INC

  公开号：WO2014164905A1

  公开（公告）日：2014-10-09

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are substituted 3-phenylpropylamine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.